EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Comprehensive Genomic Profiling in Advanced Non‐Small Cell Lung Cancer: A Real‐World Cohort Study in Finland

Kirsi Hormalainen iD, Kaisa Marttila iD, Matti Nykter, Toomas Uibu, Jarkko Ahvonen iD, Vidal Fey, Mauri Keinänen, Maarit Bärlund, Arja Jukkola

Cancer Medicine · 2025

DOI: 10.1002/cam4.71250 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Kirsi Hormalainen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Tampere University Hospital, Tampere, Finland. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tampereen Tuberkuloosisäätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non‐small cell lung cancer (NSCLC) is a disease with a low survival rate and poor prognosis. Targeted therapies have improved treatment outcomes as driver mutations have been identified, especially in adenocarcinomas. Comprehensive genomic profiling (CGP) provides insights into the genetic mutation profile of cancer and helps identify actionable mutations. The mutational landscape of cancer varies based on the patient's ethnic background, and there is limited information on the genetic profile of NSCLC within the Finnish population. Material and Methods We analysed the genetic mutational profile of 96 advanced NSCLCs that underwent CGP between November 2021 and March 2023 at Tampere University Hospital. Additionally, we compared the genomic alterations in our cohort with those in the international datasets.

Results

Clinically actionable alterations associated with a targeted therapy were identified in 45% of patients, including 63% of never‐smokers and 41% of ever‐smokers. The most common actionable alteration was KRAS G12C (18%), followed by EGFR alterations (14%). However, only 33% of the patients with an actionable alteration received targeted therapy. The median tumour mutational burden (TMB) was 5, with 31% of patients exhibiting a TMB greater than 10.

Conclusions

CGP affects the treatment strategies for NSCLC. Nearly half of our entire cohort had a genetic alteration eligible for approved targeted therapies. Besides these findings, CGP provides additional data to assess treatment decisions and outcomes, including co‐occurring genetic alterations and TMB. In real‐world clinical practice, the practical application of this information can be restricted by the varying unavailability of optimal treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkers, TumorHumansMaleFemaleFinlandAgedMiddle AgedMutationAged, 80 and overCohort StudiesAdultErbB ReceptorsPrognosisProto-Oncogene Proteins p21(ras)GenomicsGene Expression Profiling

Stichwörter der Autor:innen

biomarkercomprehensive genomic profilingnon‐small cell lung cancertargeted therapy

Substanzen

Biomarkers, TumorErbB ReceptorsEGFR protein, humanProto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Tampere University Hospital, Tampere, Finland.
  • Tays Cancer Centre, Tampere University Hospital, Tampere, Finland.
  • Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Department of Oncology, Tampere University Hospital, Tampere, Finland.
  • Fimlab Laboratories, Tampere, Finland.

ORCID-Profile: Kirsi Hormalainen, Kaisa Marttila, Jarkko Ahvonen

Förderung

  • Tampereen Tuberkuloosisäätiö

Zitieren

APA

Hormalainen, K., Marttila, K., Nykter, M., Uibu, T., Ahvonen, J., Fey, V., Keinänen, M., Bärlund, M., & Jukkola, A. (2025). Comprehensive Genomic Profiling in Advanced Non‐Small Cell Lung Cancer: A Real‐World Cohort Study in Finland. Cancer Medicine. https://doi.org/10.1002/cam4.71250

Vancouver

Hormalainen K, Marttila K, Nykter M, Uibu T, Ahvonen J, Fey V, et al. Comprehensive Genomic Profiling in Advanced Non‐Small Cell Lung Cancer: A Real‐World Cohort Study in Finland. Cancer Medicine. 2025. doi:10.1002/cam4.71250

BibTeX
@article{Hormalainen2025,
  author = {Hormalainen, Kirsi and Marttila, Kaisa and Nykter, Matti and Uibu, Toomas and Ahvonen, Jarkko and Fey, Vidal and Keinänen, Mauri and Bärlund, Maarit and Jukkola, Arja},
  title = {Comprehensive Genomic Profiling in Advanced Non‐Small Cell Lung Cancer: A Real‐World Cohort Study in Finland},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71250}
}
Kostenlos starten →